ArticleWorld journal of psychiatry2026
Effects of celecoxib combined with duloxetine on chronic pain, depression, and anxiety in patients with knee osteoarthritis.
Article in World journal of psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKnee osteoarthritis (KOA), a common disabling pathology characterized by knee joint pain, swelling, and functional impairment, primarily affects middle-aged and older adults. In addition to physical limitations, chronic pain often leads to psychological problems, including anxiety and depression, which further impact patients' quality of life.
aimTo examine the efficacy and safety of celecoxib plus duloxetine in managing chronic pain, anxiety, and depression in patients with KOA.
methodsA retrospective analysis was conducted on 123 patients with KOA treated at our center between February 2020 and February 2023. Of these, 66 received celecoxib plus duloxetine, and 57 received celecoxib alone. Outcomes were assessed using the Visual Analog Scale (VAS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the Self-Rating Anxiety Scales (SAS)/Self-Rating Depression Scales (SDS). Safety was evaluated by monitoring changes in liver function enzymes (alanine aminotransferase, aspartate aminotransferase), creatinine, and blood urea nitrogen.
resultsPatients receiving celecoxib plus duloxetine showed significantly greater reductions in VAS and WOMAC and greater improvements in SAS and SDS scores compared with those receiving celecoxib alone. Hepatorenal function did not differ significantly between the treatment groups. Logistic regression analysis identified patient age, educational background, and treatment regimen as independent predictors of inadequate improvement in negative emotional symptoms.
conclusionIn patients with KOA, celecoxib plus duloxetine effectively mitigates chronic pain and improves anxiety and depressive symptoms without increasing adverse hepatic or renal effects. These findings support its use as a safe and effective treatment option.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.